Ben Tempel

Ben Tempel serves as Principal at Frameshift Advisors since 2022 and holds an Adjunct Professor position in Biotechnology at The Johns Hopkins University, starting in October 2024. Prior roles include CEO of HBVTECH from 2022 to 2024, Strategic Advisor in Cell and Gene Therapy at Expression Therapeutics, Inc. from 2020 to 2022, and Vice President of Corporate Strategy and Development at AnovoRx from 2018 to 2022. Additional experience encompasses positions in strategy and development at TruGreen, Accredo, and Sunrise Senior Living. Ben Tempel's academic credentials feature a Master of Science in Regenerative and Stem Cell Technologies from The Johns Hopkins University, an MBA from Emory University's Goizueta Business School, dual Bachelor's degrees in Civil and Industrial Engineering from the Georgia Institute of Technology, as well as various certificates from Stanford University School of Medicine and Harvard Medical School in genetics and genomics.